Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer

NICE technology appraisals [TA284] Published date:

What has NICE said?

NICE does not recommend bevacizumab, given with paclitaxel and carboplatin, as first-line treatment for advanced ovarian cancer (including fallopian tube and primary peritoneal cancer).

Why has NICE said this?

NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. Bevacizumab does not provide enough benefit to patients to justify its high cost, so NICE did not recommend it.

Get involved